AbCellera (ABCL) Stock Surges 6% on Menopause Treatment Phase 2 Data Reveal

Key Highlights

• ABCL shares climbed 6.13% on August 7, reaching an intraday peak of $6.53 with a 10.3% gain after Q2 results and clinical updates
• Phase 2 top-line data for non-hormonal menopause candidate ABCL635 scheduled for pre-market release on August 10
• Second-quarter revenue declined 76.3% versus prior year to $4.05 million, while net loss expanded to $55.4 million
• Cash reserves of $567 million and total available liquidity exceeding $675 million provide financial runway
• Collaborations with Vertex and Jazz generated over $110 million in upfront payments

Shares of AbCellera Biologics (ABCL) surged as high as 10.3% to reach $6.53 during trading on August 7, ultimately settling with a 6.13% gain as the market digested second-quarter financial results alongside news of an imminent clinical catalyst.

AbCellera Biologics Inc., ABCL

The biotechnology firm disclosed plans to unveil top-line Phase 2 data for its menopause treatment candidate ABCL635 prior to market opening on August 10, 2026. Management will host an investor conference call and webcast at 4:30 a.m. Pacific Time the same day.

ABCL635 represents a potentially first-in-class non-hormonal antibody approach aimed at the NK3 receptor, intended to diminish both frequency and intensity of vasomotor symptoms experienced by postmenopausal women. The therapy entered human trials in July 2025.

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 https://t.co/iKiCXMLGZepic.twitter.com/haJhACRwFq

— AbCellera (@AbCelleraBio) August 7, 2026

The Phase 2 study recruited roughly 80 postmenopausal participants in a randomized, double-blind, placebo-controlled format. The trial is registered under identifier NCT07118891.

This upcoming disclosure marks AbCellera’s inaugural Phase 2 readout derived from its GPCR and ion channel discovery platform, positioning it as a significant inflection point for the organization.

Second Quarter Financials Show Continued Pressure

The financial performance for Q2 revealed ongoing challenges. Total revenue registered at $4.05 million, representing a 76.3% decline from the $17.08 million reported in the comparable 2025 period. Net losses deepened 59.7% to $55.4 million.

Earnings per share on a basic basis came to a loss of $0.18, widening from the $0.12 per share loss recorded twelve months earlier. Research and development expenditures totaled roughly $46 million during the three-month period.

On the development front, progress continued. AbCellera’s clinical portfolio now includes nine programs in Phase 1 and one in Phase 2, compared to 11 Phase 1 candidates and zero Phase 2 assets at the same point last year.

ABCL575 has completed Phase 1 dose escalation, with top-line data anticipated in the fourth quarter of 2026.

Strong Liquidity Position Provides Runway

While operational losses persist, the company’s financial foundation remains solid. AbCellera closed the quarter holding $567 million in cash equivalents and commanding more than $675 million in total accessible liquidity.

Strategic alliances with Jazz Pharmaceuticals and Vertex, centered on T cell engager development programs, delivered upfront cash consideration exceeding $110 million.

Skeptics highlight that such payments represent non-recurring transaction proceeds rather than sustainable revenue streams. Milestone achievements and royalty income have yet to reach levels sufficient to counterbalance persistent operating deficits.

The latest analyst coverage on ABCL carries a Buy recommendation with a $12.00 price objective. The company’s market capitalization currently stands at approximately $1.74 billion.

Market focus now shifts entirely to the August 10 data readout for ABCL635.

The post AbCellera (ABCL) Stock Surges 6% on Menopause Treatment Phase 2 Data Reveal appeared first on Blockonomi.